NCT01480011View on ClinicalTrials.gov

A Pilot Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

December 31, 2012

Conditions
Oral Mucositis
Interventions
DRUG

lactobacillus CD2 lozenges

The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient

Trial Locations (1)

110029

All India institute of Medical sciences, New Delhi

All Listed Sponsors
lead

All India Institute of Medical Sciences

OTHER

NCT01480011 - A Pilot Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter